- The company's growing patent portfolio now has over 150 patent applications and issued patents that cover the design and manufacture of metasurfaces, as well as chips, modules, products, and image processing.
- Metalenz advances its comprehensive IP portfolio supporting product innovations that simplify and improve 3D depth sensing, such as single element dot pattern projectors.
- Metalenz continues to build on core innovations, integrating polarization-based metasurfaces into next-gen image sensing solutions as the metasurface market and use cases for consumer sensing rapidly expand.
BOSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Metalenz, a specialist in metasurface innovation and commercialization, today announces the expansion of its product and patent portfolio, which now encompasses metasurface technology and system level applications for secure biometrics. The announcement comes after issuance of patents for single element dot pattern projectors, and face recognition with polarization. These innovations enable more compact 3D sensing and biometric solutions that simplify and enhance performance across a range of high-volume consumer and industrial markets.
3rd party teardowns by Yole group have revealed metasurfaces in smartphones and tablets made by top consumer OEMs, confirming widespread mass market adoption of this new optical technology projected to exceed $2 billion in revenue by 2029 (Yole Group, Optical Metasurfaces, 2024 Report).
Metalenz holds an exclusive worldwide license to metasurface intellectual property developed in the Capasso Lab at Harvard John A. Paulson School of Engineering and Applied Sciences. Combined with its own rapidly growing portfolio, Metalenz now has more than 150 patent applications and issued patents. The portfolio supports Metalenz's existing business for simplifying 3D sensing modules as well as new products like Polar ID, where the company is providing a full-stack biometric solution from the metasurface design and hardware all the way through machine learning algorithms.
“By enabling the shift of optics production into semiconductor manufacturing, the metasurface innovation developed in the Capasso Lab and commercialized by Metalenz has redefined the sensing ecosystem. Metalenz has developed a comprehensive set of know-how, patents and algorithms designed around our core technology that is further expanding our market leadership,” said Metalenz CEO and Co-founder Rob Devlin. “We're expanding the market for metasurface optics and use cases in consumer sensing, and will continue to build on our foundational technology as we design complete solutions around our metasurface optic for secure biometrics and new applications of polarization.”
About Metalenz
Metalenz is investing in driving innovation in optics with metasurface technology, providing solutions that address the possibilities of mobile imaging and sensing. Metalenz is the first company to bring metasurfaces to mass markets, with over 140 million of its meta-optics already integrated in consumer devices, combining the functionality of three or four complex lenses and components into a single flat device, mass produced in existing semiconductor foundries. The company's Polar ID solution is an ultra-secure, small, and affordable face authentication product for consumer devices that harnesses the unique polarized light sorting capabilities of metasurfaces, enabling machine vision to see beyond the limits of current systems. metalenz.com
Press Contact
Carly Glovinski, Senior Marketing Manager
media@metalenz.com
-
越捷航空献礼中国旅客:0元机票限时畅飞 尊享20公斤免费托运行李(北京,2025年8月18日)越南最大的民营航空公司越捷航空(Vietjet)诚邀中国旅客探秘越南风情,即日起推出直飞航线空前特惠,适用于北京、上海、广州、西安、成都五大枢纽直飞2025-08-19
-
南京交通职业技术学院轨道交通学院分团委:开展“星火坐标:红色基因青春测绘队”暑期社会实践活动为深入学习党的光辉历史,传承红色基因,汲取奋进力量,在庆祝中国人民抗日战争暨世界反法西斯战争胜利80周年、全民族抗战爆发88周年之际,轨道交通学院“星火坐2025-08-19
-
推普支教融乡兴,稚语童声谱新篇(通讯员 刘玉涵 熊舒妍)2025年7月1日至15日,湖北大学“稚语童声”实践团队在湖北省黄冈市英山县石头咀镇冯家畈村、杜家山村开展了为期半个月的推普助力乡村振兴2025-08-19
-
绿色能源新标杆!瑞达固态铅电池成功赋能立讯精密昆山16MWh储能电站为积极响应加快推动新型储能示范应用和规模化发展的政策号召,提升电力系统调节能力,促进新能源消纳,构建适应大规模高比例新能源发展需求的新型电力系统,瑞达国际集团2025-08-19
-
迈威生物靶向 CDH17 ADC 创新药 7MW4911 临床试验申请获得 FDA 许可上海2025年8月19日 美通社 -- 迈威生物(688062.SH),一家全产业链布局的创新型生物制药公司,宣布其自主研发的靶向 CDH17 ADC 创新药(研发代号:7MW4911)的临床试验申请正式2025-08-19